Every 10-Q that Trevi Therapeutics (TRVI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TRVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRVI filings page.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease and refractory chronic cough. For the three months ended June 30, 2026, it recorded a net loss of $17,797 (in thousands), wider than $12,301 (in thousands) a year earlier, as research and development expenses increased to $15,152 (in thousands) and general and administrative expenses to $5,357 (in thousands).
Spending rose primarily to support the new Phase 3 OCEAN-1 trial in IPF-related chronic cough, preparation for the Phase 3 OCEAN-2 trial, the Phase 2b LAKE trial in refractory chronic cough and Phase 1 NDA-supportive studies. As of June 30, 2026, Trevi held $318.9 million in cash, cash equivalents and marketable securities and had an accumulated deficit of $360.8 million, and it believes existing liquidity will fund operating and capital needs for at least 12 months while it advances these late-stage programs.
Trevi Therapeutics reported a net loss of $13.2 million for the three months ended March 31, 2026, compared with $10.3 million a year earlier, as it advances its chronic cough drug Haduvio. Research and development expenses rose to $9.9 million, driven by Phase 3 preparation in idiopathic pulmonary fibrosis (IPF), Phase 2b work in refractory chronic cough (RCC) and NDA‑supportive studies, while general and administrative costs increased to $5.0 million.
The company ended the quarter with $171.8 million in cash, cash equivalents and marketable securities, and subsequently strengthened its balance sheet through an April 2026 underwritten equity offering that generated gross proceeds of $173.4 million and approximately $162 million in net proceeds. Management believes existing resources will fund operations for at least 12 months as Trevi progresses parallel Phase 3 IPF-related chronic cough trials, a Phase 2b RCC trial, a Phase 2b non‑IPF ILD trial and multiple Phase 1 studies.
Trevi Therapeutics (TRVI) filed its Q3 2025 10‑Q, reporting a net loss of $11.8 million (basic and diluted $(0.08) per share) versus $13.2 million (($(0.13)) a year ago. Operating expenses were $13.9 million, comprised of $10.1 million in R&D and $3.8 million in G&A. Interest income contributed $2.1 million in the quarter.
For the nine months, net loss was $34.4 million. The balance sheet strengthened: cash and cash equivalents $56.9 million and marketable securities $138.1 million at September 30, 2025, supporting total current assets $198.3 million. Stockholders’ equity was $189.8 million and total liabilities were $9.6 million.
Year‑to‑date financing cash inflows were $120.7 million, including $108.2 million from a June 2025 underwritten offering and $10.8 million from warrant exercises. Shares outstanding were 128,215,113 at September 30, 2025; 128,230,134 were outstanding as of October 31, 2025.